Browsing by Author "Yeh, CT"

Now showing 1 - 2 of 2

A system for a new two-dimensional code: Secure 2D code
(1998-10-01)
Yeh, CT
;
Chen, LH
;
資訊工程學系
;
Department of Computer Science
A new 2D code called Secure 2D code is designed in this paper, both encoder and decoder are also proposed. Secure 2D code can store any kind of data and provides high security. With regard to security, the input data is divided into two parts: general and secret. The general data is transformed into a 2D code pattern, then secret data is hidden in the 2D code pattern. To raise the reading speed and allow various reading environments, some features are added around the 2D code pattern boundary. As to the reliability, RS code is adopted to treat damaged patterns.
Inhibition of hepatitis C virus replication by antimonial compounds
(2005-10-01)
Hwang, DR
;
Lin, RK
;
Leu, GZ
;
Lin, TY
;
Lien, TW
Chronic hepatitis C virus (HCV) infection is a worldwide health problem causing serious complications, such as liver cirrhosis and hepatoma. Alpha interferon (IFN-alpha) or its polyethylene glycol-modified form combined with ribavirin is the only recommended therapy. However, an alternative therapy is needed due to the unsatisfactory cure rate of the IFN-based therapy. Using a modified reporter assay based on the HCV subgenomic-replicon system, we found that sodium stibogluconate (SSG), a compound used for leishmania treatment, suppressed HCV replication. We have previously reported that SSG is effective at inhibiting HCV replication in a cell line permissive for HCV infection/replication and in an ex vivo assay using fresh human liver slices obtained from patients infected with HCV (26). In this study, we show that the SSG 50% inhibitory dose for HCV replication is 0.2 to 0.3 mg/ml (equivalent to 345 to 517 mu M of Sb) in the HCV subgenomic-replicon system. We also found that SSG and IFN-alpha exert a strong synergistic anti-HCV effect in both the traditional isobologram analysis and the median effect principle (CalcuSyn analysis). The combination of SSG and IFN-alpha could sustain the antiviral response better than SSG or IFN-alpha alone. The results suggest that SSG may be a good drug candidate for use in combination with other therapeutics, such as IFN-alpha and ribavirin, to treat HCV infection.